文献速递贫血与红细胞疾病

转铁蛋白受体2(Tfr2)基因缺失使输血依赖型β-地中海贫血小鼠模型摆脱输血依赖

Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
PubMed 文献 · Am J Hematol · 2022-08-10

本研究在Hbbth1/th2输血依赖型β-地中海贫血小鼠模型中证明,骨髓Tfr2缺失可改善贫血、红细胞形态及无效造血,并足以避免长期输血需求、防止慢性贫血所致死亡、减少输血相关铁过载等并发症;TFR2靶向可能成为输血依赖型β-地中海贫血的治疗选择。

要点

  • 骨髓Tfr2缺失改善Hbbth1/th2小鼠的贫血、红细胞形态和无效造血。
  • 骨髓Tfr2缺失足以使Hbbth1/th2小鼠避免长期输血依赖并防止慢性贫血死亡。
  • TFR2靶向可能成为输血依赖型β-地中海贫血的有前景治疗选择。

核心结论

  • 骨髓Tfr2缺失可改善Hbbth1/th2输血依赖型β-地中海贫血小鼠模型的贫血、红细胞形态和无效造血。
  • 骨髓Tfr2缺失足以使Hbbth1/th2小鼠避免长期输血需求、防止慢性贫血所致死亡并减少输血相关并发症如进行性铁过载。
  • 作者认为TFR2靶向可能也是输血依赖型β-地中海贫血的有前景治疗选择。

研究设计与样本

  • 研究在Hbbth1/th2输血依赖型β-地中海贫血小鼠模型中进行骨髓Tfr2缺失实验。
  • 原文未报告样本量、分组数及随访时长。

主要发现

  • 骨髓Tfr2缺失改善Hbbth1/th2小鼠的贫血、红细胞形态和无效造血。
  • 该效应与α-珠蛋白表达下降(部分纠正与β-珠蛋白链的不平衡并限制错误折叠血红蛋白沉淀)及未折叠蛋白反应激活下降相关。
  • 骨髓Tfr2缺失足以避免Hbbth1/th2动物生存所需的长期输血,防止慢性贫血所致死亡并减少进行性铁过载等输血相关并发症。

关键数值与推荐

  • 原文未报告具体数值、阈值或推荐等级。

临床怎么用

  • 原文结论认为TFR2靶向可能也是输血依赖型β-地中海贫血的有前景治疗选择,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-thalassemia is a genetic disorder caused by mutations in the β-globin gene, and characterized by anemia, ineffective erythropoiesis and iron overload. Patients affected by the most severe transfusion-dependent form of the disease (TDT) require lifelong blood transfusions and iron chelation therapy, a symptomatic treatment associated with several complications. Other therapeutic opportunities are available, but none is fully effective and/or applicable to all patients, calling for the identification of novel strategies. Transferrin receptor 2 (TFR2) balances red blood cells production according to iron availability, being an activator of the iron-regulatory hormone hepcidin in the liver and a modulator of erythropoietin signaling in erythroid cells. Selective Tfr2 deletion in the BM improves anemia and iron-overload in non-TDT mice, both as a monotherapy and, even more strikingly, in combination with iron-restricting approaches. However, whether Tfr2 targeting might represent a therapeutic option for TDT has never been investigated so far. Here, we prove that BM Tfr2 deletion improves anemia, erythrocytes morphology and ineffective erythropoiesis in the Hbbth1/th2 murine model of TDT. This effect is associated with a decrease in the expression of α-globin, which partially corrects the unbalance with β-globin chains and limits the precipitation of misfolded hemoglobin, and with a decrease in the activation of unfolded protein response. Remarkably, BM Tfr2 deletion is also sufficient to avoid long-term blood transfusions required for survival of Hbbth1/th2 animals, preventing mortality due to chronic anemia and reducing transfusion-associated complications, such as progressive iron-loading. Altogether, TFR2 targeting might represent a promising therapeutic option also for TDT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Di Modica SM, Tanzi E, Olivari V, et al. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia. Am J Hematol. 2022. PMID: 36071579. doi:10.1002/ajh.26673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。